Brokerages Set Xencor, Inc. (NASDAQ:XNCR) PT at $36.56

Xencor, Inc. (NASDAQ:XNCR) has earned a consensus recommendation of “Buy” from the nine analysts that are presently covering the firm, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $36.56.

A number of research analysts have recently weighed in on the company. Wells Fargo & Company began coverage on Xencor in a report on Thursday, December 12th. They issued an “overweight” rating and a $37.00 target price on the stock. Royal Bank of Canada raised their price objective on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, September 26th. Wedbush reaffirmed an “outperform” rating and set a $38.00 price objective on shares of Xencor in a report on Thursday, November 7th. BMO Capital Markets reiterated an “outperform” rating and issued a $34.00 target price (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th.

Xencor Stock Performance

XNCR opened at $20.60 on Thursday. Xencor has a 1-year low of $15.31 and a 1-year high of $27.24. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -6.44 and a beta of 0.72. The company’s fifty day moving average price is $24.18 and its two-hundred day moving average price is $20.99. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.27. The company had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm’s revenue was down 81.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.40) EPS. On average, analysts expect that Xencor will post -3.71 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP John R. Desjarlais sold 68,684 shares of the company’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the sale, the vice president now directly owns 200,104 shares in the company, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Alan Bruce Montgomery sold 1,421 shares of the firm’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total value of $38,409.63. Following the completion of the transaction, the director now directly owns 9,140 shares of the company’s stock, valued at $247,054.20. The trade was a 13.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 136,050 shares of company stock worth $3,277,609. Insiders own 5.23% of the company’s stock.

Institutional Investors Weigh In On Xencor

Large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. lifted its holdings in shares of Xencor by 147.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock worth $62,748,000 after acquiring an additional 1,858,440 shares during the last quarter. Logos Global Management LP raised its position in Xencor by 130.8% during the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $28,395,000 after purchasing an additional 850,000 shares in the last quarter. RA Capital Management L.P. bought a new stake in Xencor during the third quarter worth about $11,563,000. RTW Investments LP purchased a new position in shares of Xencor in the 3rd quarter worth about $11,563,000. Finally, Braidwell LP bought a new position in shares of Xencor during the 3rd quarter valued at about $9,380,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.